Industry News (Joint Ventures)

Agreement Involves Gene Repair Technology

Published in Gene Therapy Weekly, October 7th, 1996

Kimeragen, Inc., Newtown, Pennsylvania, and the Perkin-Elmer Corp., Norwalk, Connecticut, have signed an agreement under which PE Applied Biosystems, synthesizes and supplies to Kimeragen the oligonucleotide compounds developed from Kimeragen's chimeraplasty gene repair technology.

Kimeragen has been developing chimeraplasty as a potential treatment for genetic diseases, cancer and viral diseases. PE Applied Biosystems and Kimeragen also make the chimeric compounds available for non-profit academic research through PE Applied Biosystems' custom oligonucleotide synthesis service.

Chimeraplasty is a gene repair technology designed to correct genetic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-10-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry